Content area
Full Text
A 3-year-old biotech startup in which Senmed Medical Ventures of Blue Ash is an investor has landed a $40 million venture capital infusion.
Merix Bioscience Inc. of Durham, N.C., is developing cancer vaccine technology. Senmed is an early investor and helped manage Merix until mid-January, when Mark Weedon joined the company as its first CEO. Senmed's Clint "Skip" Dederick remains chairman of the Merix board of directors.
In April, Merix closed on $20 million of second-round funding. But that fell about $5 million...